Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDTTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CDT Equity's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CDT Equity's regulatory disclosures and financial reporting.
CDT Equity Inc. approved and is implementing a 1-for-10 reverse stock split of its common stock to ensure continued compliance with the Nasdaq bid-price rule. The split becomes effective on July 17, 2026 at 5:00 p.m. Eastern Time, and the shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market on July 20, 2026 under the existing symbol CDT, with a new CUSIP number 20678X601.
Each block of ten issued and outstanding shares will be combined into one share, with the par value remaining $0.0001 per share and other terms unchanged. No fractional shares will be issued; stockholders will receive cash in lieu based on the July 17, 2026 closing price. Following the reverse split, outstanding common shares are expected to be reduced to approximately 631,077, and proportional adjustments will apply to equity awards, convertible securities, warrants, and equity incentive plan reserves.
CDT Equity Inc., a data-driven pharmaceutical development company, reported a first‑quarter 2026 net loss of approximately $4.1 million, slightly improved from 2025, on operating expenses of $3.7 million. Research and development was $0.8 million and general and administrative expenses were $2.9 million for the three months ended March 31, 2026.
The balance sheet changed markedly after a 20% equity investment in Sarborg, recorded at $123.0 million and carried at $122.9 million as of March 31, 2026. This drove total assets to $127.1 million and additional paid‑in capital to $177.6 million. Shares outstanding increased to 4,722,457, largely from warrant exercises and stock issued for services and investments.
Liquidity remains strained. As of March 31, 2026, cash and cash equivalents were $0.1 million, with cash used in operating activities of $1.9 million. Management discloses that these factors, despite access to an at‑the‑market program and a $25 million equity line, raise substantial doubt about the company’s ability to continue as a going concern. The company also carries a $9.6 million litigation liability related to the Strand judgment and is involved in additional intellectual property proceedings.
CDT Equity Inc. updated the terms of an existing financing arrangement with J.J. Astor & Co. by entering into an Amended and Restated Loan Agreement and Amended and Restated Senior Secured Convertible Promissory Note on June 30, 2026. The original Note has a principal amount of $1,971,000, with the Company receiving $1,460,000 in loan proceeds funded in two tranches. The amendment closes the second tranche and reschedules repayment so that twenty-four equal weekly installments of $82,125 now begin on July 10, 2026, instead of the previously agreed start date of June 18, 2026. The filing also records this as a direct financial obligation and attaches the full amended note and loan agreement as exhibits.
CDT Equity Inc. reported that its audit committee dismissed CBIZ CPAs P.C. as independent auditor and approved Carr, Riggs & Ingram, L.L.C. (CRI) as the new independent registered public accounting firm, effective June 23, 2026.
CBIZ CPAs’ audit report on the year ended December 31, 2025 contained an explanatory paragraph about substantial doubt regarding CDT Equity’s ability to continue as a going concern. The company also disclosed previously identified material weaknesses in internal control over financial reporting, including limited segregation of duties, lack of formal review processes, recurring errors, inadequate control design, restatements, and inconsistent review of related-party transactions. The company states there were no disagreements with CBIZ CPAs on accounting or auditing matters, and it had not consulted CRI on accounting issues before the engagement.
CDT Equity Inc. investors Prospect Capital Securities, Prospect Finance and Mark Taylor filed Amendment No. 1 to their Schedule 13D to report that they no longer beneficially own CDT Equity common stock. The filing describes open‑market sales on June 18, 2026 that reduced their holdings to zero, representing approximately 0.0% of the 4,722,458 shares outstanding as of June 22, 2026. The amendment is characterized as an exit filing and notes a previously effected 1‑for‑25 reverse stock split on March 26, 2026, which is reflected in the share figures reported.
CDT Equity Inc. disclosed that entities associated with major shareholder Mark Taylor sold a combined 2,068,000 shares of Common Stock in open-market transactions on June 18, 2026. Prospect Capital Securities Limited sold 1,469,711 shares at prices including $1.44 and $0.7052 per share, while Prospect Finance Limited sold 598,289 shares at prices including $1.25–$1.67 and $0.751 per share. Following these sales, each entity reported holding zero CDT Equity common shares. The reported share amounts give effect to a 1-for-25 reverse split effective as of March 26, 2026.
CDT Equity Inc. has restructured its financing, eliminating over $6.3 million of legacy obligations while entering a new secured convertible loan facility. The company repaid a $5,737,500 A.G.P. convertible note and will repay $555,555.56 to Ascent Partners, leaving a single senior secured convertible note with J.J. Astor & Co.
Under the new Loan Agreement, CDT will receive up to $1,460,000 against a senior secured convertible promissory note with a principal amount of $1,971,000, repayable in twenty-four weekly installments of $82,125. The note can be converted into common stock after six months at a variable price tied to the stock’s volume-weighted average price and subject to Nasdaq Rule 5635(d) and ownership caps of 4.99% or, at the lender’s election, 9.99%.
CDT also issued warrants to purchase 912,500 shares at $0.72 per share, with all conversion and warrant issuance above 19.99% of current outstanding shares requiring stockholder approval. The note is interest-free unless a default occurs, in which case the amount due increases to 120% of the outstanding balance and accrues interest at 19% per annum, compounded daily.
CDT Equity Inc. Schedule 13G reports a group of affiliated entities and individuals collectively associated with Ascent Partners Fund LLC that hold or have rights to 543,645 shares of Common Stock, representing 9.9% of the class based on 4,858,350 shares outstanding as reported in the Prospectus. The shares comprise the maximum issuable under a Directed Stock Purchase Agreement dated January 16, 2026 (the "ELOC Agreement") and are subject to a 9.99% beneficial ownership limit (the "Blocker"). As of June 5, 2026, Ascent holds no shares directly, there are 543,645 shares issuable under the ELOC Agreement (the Blocker maximum), and an internal reorganization on June 1, 2026 moved management such that Dominion Capital Holdings LLC ceased to hold voting or dispositive power and Eagle Claw became a >5% beneficial owner.
CDT Equity Inc. reported receiving a Nasdaq deficiency notice because it did not file its Form 10‑Q for the quarter ended March 31, 2026 on time, as required by Nasdaq Listing Rule 5250(c)(1) governing periodic filings. The notice does not immediately affect trading or the listing of its common stock or warrants on The Nasdaq Capital Market.
Nasdaq has given the company until July 20, 2026 to submit a plan to regain compliance. CDT Equity anticipates filing the delayed Form 10‑Q once its review process is complete, which it expects will restore compliance with the periodic filing requirement.
CDT Equity Inc. Schedule 13G: a Nirland/Stockton/Rowland/Dovet group reports shared beneficial ownership of 75,315 shares of Common Stock, equal to 1.6% of the class. The group states it exceeded 5% on 02/19/2026, which triggered the reporting obligation; ownership has since decreased below 5% as of this filing. The filing lists shared voting and dispositive power for 75,315 shares and includes a Joint Filing Agreement dated 05/20/2026.